Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight

- ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. - ASC30 titrated weekly to target dose demonstrated...

AGIBOT Announces the Rollout of Its 5,000th Mass-Produced Humanoid Robot

AGIBOT Announces the Rollout of Its 5,000th Mass-Produced Humanoid Robot

SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- AGIBOT, a leading robotics company specializing in embodied intelligence, today announces the official roll-out of its 5,000th mass-produced humanoid robot at its factory. This milestone represents a step...

Connexus Travel Launches FIFA World Cup 26™ Content Series

Connexus Travel Launches FIFA World Cup 26™ Content Series

Multi-platform rollout featuring match analysis, player profiles, team previews and travel guides as World Cup excitement intensifies post-draw HONG KONG, Dec. 8, 2025 /PRNewswire/ -- Connexus Travel today announces the launch of its dedicated FIFA...

House of Rose Professional Announces 2026 World Tour of Break the Ceiling Touch the Sky® Summit

House of Rose Professional Announces 2026 World Tour of Break the Ceiling Touch the Sky® Summit

Partnership Plans to leverage the 2026 Tour now open for Americas, Europe, Middle East & Africa, India and World Editions of summit SINGAPORE, NEW YORK and LONDON, Dec. 8, 2025 /PRNewswire/ -- House of Rose Professional today announced the...

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...

Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- The Dulwich College Ranjit Murugason Sustainability Fund is pleased to announce renewed support from LGT Bank Singapore ("LGT"), reinforcing a three-year collaboration that has helped Dulwich College...

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT...

Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting

Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated,...

Strutt ev¹ the CES 2026 Best of Innovation Winner Announces Super Early Bird Begins

Strutt ev¹ the CES 2026 Best of Innovation Winner Announces Super Early Bird Begins

The awards-winning robotics company officially kicks off its pre-order window ahead of its main launch at CES 2026. SINGAPORE, Dec. 6, 2025 /PRNewswire/ -- Strutt, a Singapore-incorporated robotics company advancing smart everyday vehicle, announced...

Tuniu Announces Unaudited Third Quarter 2025 Financial Results

Tuniu Announces Unaudited Third Quarter 2025 Financial Results

NANJING, China, Dec. 5, 2025 /PRNewswire/ -- Tuniu Corporation (NASDAQ: TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced its unaudited financial results for the third quarter ended September 30,...

  • 1
  • ...
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • ...
  • 157
  • menu
    menu